Renault's New China Strategy To Focus On LCV, EV; Stock Up

French automaker Renault SA (RNSDY.PK) announced Tuesday its new Strategy for China, under which the company will focus on light commercial vehicles or LCV and electric vehicles or EV.

Renault has entered into a preliminary agreement, under which the company will transfer its shares in Dongfeng Renault Automotive Company Ltd or DRAC to Dongfeng Motor Corp. DRAC will stop its Renault brand-related activities.

Renault will continue to provide high quality aftersales service for its 300,000 customers through Renault dealers but also through Alliance synergies.

Furthermore, Renault and Dongfeng will continue to cooperate with Nissan on new generation engines like components supply to DRAC and diesel license to Dongfeng Automobile Co., Ltd.

The company said its LCV business is operated through Renault Brilliance Jinbei Automotive Co., Ltd. or RBJAC. EV business will be developed through the two existing joint ventures, such as eGT New Energy Automotive Co., Ltd and Jiangxi Jiangling Group Electric Vehicle Co. Ltd.

The company expects the new China strategy to enhance its competitive advantages to sustain long-term presence in the Chinese market and maximize synergies with Nissan.

In Paris, Renault shares were trading at 19.08 euros, up 2.90 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT